Navigation Links
AstraZeneca Receives Complete Response Letter From US FDA For BRILINTA™ (Ticagrelor Tablets)
Date:12/16/2010

WILMINGTON, Del., Dec. 16, 2010 /PRNewswire/ -- AstraZeneca (NYSE: AZN) announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for ticagrelor (BRILINTA™).

(Logo: http://photos.prnewswire.com/prnh/20091027/PH99766LOGO)

In the CRL, the FDA requested additional analyses of the PLATO data. The agency did not request that additional studies, including clinical studies, be conducted as a prerequisite for approval of the ticagrelor NDA.

AstraZeneca is evaluating the contents of the CRL and will respond to the agency's request for additional analyses of the PLATO data as soon as possible. The company remains confident in the NDA submission for ticagrelor and in its ability to respond to the agency's questions.

"Our highest priority is to provide the requested PLATO analyses to the FDA and progress to completion of the BRILINTA NDA review," said Martin Mackay, President, Research & Development, AstraZeneca.

NOTES TO EDITORS

About BRILINTA™ (ticagrelor tablets)

BRILINTA is an oral antiplatelet treatment for acute coronary syndromes (ACS). BRILINTA is a direct-acting P2Y12 receptor antagonist in a chemical class called cyclopentyltriazolopyrimidines (CPTPs). BRILINTA is the first reversibly-binding oral ADP receptor antagonist.

BRILINTA is currently under regulatory review in eighteen territories around the world and was granted marketing authorization under the trade name BRILIQUE™ by the European Commission (EC) on December 6, 2010.

BRILINTA and BRILIQUE are trademarks of the AstraZeneca group of companies.

About the PLATO study

PLATO was a large (18,624 patients in 43 countries) head-to-head patient outcomes study of ticagrelor versus clopidogrel, designed to establish whether ticagrelor could achieve clinically meaningful cardiovascular and safety end points in ACS patients, above and beyond those afforded by clopidogrel. The NDA submission for ticagrelor is based on the results of a comprehensive clinical trial program, including data from the PLATO study.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. In the United States, AstraZeneca is a $14.8 billion healthcare business.

For more information about AstraZeneca in the US or the AZ&Me™ Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363).


'/>"/>
SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
5. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
6. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
7. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
8. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
9. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
10. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
11. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... , Sept. 6, 2017 NeuroRx, a clinical stage ... Ideation and Behavior (ASIB), has been granted Fast Track status ... therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + ... pivotal trial of this sequential therapy targeting patients who are ... ...
(Date:9/5/2017)... , Sept. 5, 2017  Getinge, a ... created a vibrant charitable donation program -- "Color ... support congenital heart defect research by The Children,s ... and the general public are encouraged to download ... submit the completed artwork to the gallery on ...
(Date:9/1/2017)... , Sept. 1, 2017  Explorers Like Us ( ... America,s greatest aural experiences — and deliver these experiences as ... to help people feel and heal better. ... While nothing beats a walk, ... refresh your mind, Life Environments™ is the next best thing ...
Breaking Medicine Technology:
(Date:9/21/2017)... ... , ... Japanese Zen artist couple, Fumie and Kentaro Mune, have announced to ... at Miranda Kuo Gallery on Lower East Side, NYC. This exhibition will feature some ... Wanderlust , one of the largest US yoga online media outlets in the world, ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... serving communities in northern Alabama and Georgia, is embarking on an extended charity ... utilizing modern early detection methods. , US Breast Cancer statistics show that ...
(Date:9/20/2017)... ... 2017 , ... Collins Concrete Coatings announced that they offer ... safety and cleanliness. This unique flooring system uses silver ion technology to resist ... for its antimicrobial properties. Unlike antibiotics, which kill specific microorganisms, silver ions attack ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... company specializing in medical device compliance and commercialization, has just released a ... activities. , FDA is more adamant than ever about medical device, pharmaceutical, ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... innovation, the company recently unveiled a redesigned website. The new site – still ... of building owners, architects, contractors and other industry users that Garland serves. , ...
Breaking Medicine News(10 mins):